SEC Form 4 · accession 0001104659-17-065277
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Hackman
Officer — Exec. VP and COO
Period of report
Nov 1, 2017
Accepted (ET)
Nov 1, 2017 · 5:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Nov 1, 2017 | A | 50,000 | $0.00 | A | 50,000 | D | |
| Common StockF1,F3 | Nov 1, 2017 | A | 92,500 | $0.00 | A | 142,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4,F5 | $4.71 | Nov 1, 2017 | A | 135,000 | A | — | Nov 1, 2027 | Common Shares | 135,000 | 135,000 | D |
Explanation of responses
- F1These shares are issuable pursuant to a grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.
- F2The restricted stock units vest in three equal annual installments beginning November 1, 2018.
- F3The restricted stock units vest in full on November 1, 2018.
- F4Each option has an exercise price equal to the closing price of a common share of the Issuer on the Nasdaq Global Select Market on the grant date.
- F5This stock option award will vest and become exercisable in three equal annual installments beginning November 1, 2018.